52
Participants
Start Date
August 31, 2018
Primary Completion Date
July 31, 2022
Study Completion Date
July 31, 2024
Valganciclovir
Valganciclovir is supplied as a powder for reconstitution into an oral solution. The reconstituted solution formulation comprises the following excipients: Povidone K30, fumaric acid, sodium benzoate, saccharin sodium, mannitol, flavor, and purified water.
Simple Syrup
Simple Syrup contains sucrose 85% weight by volume, purified water, and methyl paraben as a preservative along with natural preservatives. It will be flavored to match the flavor of valganciclovir.
Weill Cornell Medicine, New York
Columbia University Medical Center, New York
The Children's Hospital at Montefiore, The Bronx
Cohen Children's Medical Center, New York
SUNY Downstate Medical Center, Brooklyn
Children's Hospital of Pittsburgh, Pittsburgh
Children's Hospital of Philadelphia, Philadelphia
Children's Hospital of The King's Daughters, Norfolk
Medical University of South Carolina, Charleston
Children's Healthcare of Atlanta, Atlanta
Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville
Nationwide Children's Hospital, Columbus
Indiana University School of Medicine, Indianapolis
Mott Children's Hospital, Ann Arbor
University of Iowa, Iowa City
University of Minnesota Masonic Children's Hospital, Minneapolis
Lurie Children's Hospital, Chicago
Saint Louis Universtiy, St Louis
Children's Mercy Hospital, Kansas City
UT Southwestern, Dallas
Baylor College of Medicine, Houston
Primary Children's Hospital, Salt Lake City
University of New Mexico, Albuquerque
Rady Children's Hospital - San Diego, San Diego
UCSF Benioff Children's Hospital, San Francisco
Lucile Packard Children's Hospital, Palo Alto
Oregon Health and Science University, Portland
Seattle Children's Hospital, Seattle
Massachusetts Eye and Ear, Boston
Children's Hospital at Dartmouth-Hitchcock, Lebanon
Collaborators (1)
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Genentech, Inc.
INDUSTRY
Albert Park
OTHER